Researchers find new target to sensitize pancreatic tumors to immunotherapy

Researchers at The University of Texas MD Anderson Cancer Center have identified an epigenetic target for replication stress, called DPY30, that could sensitize pancreatic tumors to immunotherapy and serve as a predictive biomarker for patients most likely to benefit from treatment. The study, published in Cancer Research, is titled "DPY30 is an epigenetic decoupler linking replication stress to immunoediting in pancreatic cancer."